Global Alcoholic Hepatitis Treatment Market - 2023-2030

Global Alcoholic Hepatitis Treatment Market - 2023-2030

Global Alcoholic Hepatitis Treatment market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing at a CAGR of YY% during the forecast period 2023-2030.

Alcoholic hepatitis is an inflammatory liver disorder that is induced by regular increased alcohol consumption. Processing extensive quantities of alcohol can impair liver cells, leading to swelling and scarring of the liver. The condition varies from mild or severe. In severe alcoholic hepatitis cases, an individual may need a liver transplant if they do not obtain treatment or do not cease drinking alcohol in the premature phases.

The optimal therapy of alcoholic hepatitis concentrates on decreasing inflammation via the usage of glucocorticoids such as prednisolone, perhaps in combination with N-acetyl cysteine or additional drugs that subdue the immune system. Currently, only short-term gains in survival can be anticipated no therapy has been encountered to improve patient survival past 3 months. Alcohol abstinence is crucial for long-term survival.

Market Dynamics: Drivers & Restraints

Growing Prevalence of Alcohol-Related Liver Diseases

The growing prevalence of alcohol-related liver diseases is expected to boost the global market growth during the forecast period. For instance, according to the BioMed Central Ltd Journal 2023, published metal analysis article conclusion the preponderance of alcohol-related liver disease worldwide in 2022 was 4.8%. The preponderance in men was 2.9%, which was more elevated than female (0.5%). Similarly, according to the NIH, in the United States, alcohol is the top reason for liver disease. It affects over 61% of the American population, and out of the 61%, about 10% to 12% are heavy drinkers. Moreover, around 88,000 individuals are affected with alcohol-related diseases yearly, making alcohol the fourth top preventable reason for death in the U.S.

Furthermore, the growing awareness about alcohol related diseases, market developments, increase in research investments and activities are also driving the global market growth during the forecast period.

Stringent Regulatory Authorities

The stringent regulatory authorities authorizing the drug treatments are expected to hamper the global market growth. Furthermore, high drug development costs and treatment side effects are also expected to hamper the global market growth in the forecast period.

Segment Analysis

The global alcoholic hepatitis treatment market is segmented based on drug type, route of administration, distribution channel and region.

Monoclonal Antibody Drug Type Expected to Dominate Market

Owing to the increase in monoclonal antibody drug-type treatment clinical investigations in liver diseases the segment is estimated to hold a large share of the global market. For instance, in February 2023, Imperial College London reported the beginning of a study of phase 2 clinical investigation for Canakinumab 150mg/ml solution for injection. The immediate purpose of the ISAIAH investigation is to examine the probable benefits of utilizing the IL-1β antibody, Canakinumab (injection solution), for treating alcoholic hepatitis.

Moreover, recent conclusions from the pivotal phase 3 IMbrave050 trial examining atezolizumab (Tecentriq, Genentech) plus bevacizumab (Avastin, Genentech) in patients with early-stage hepatocellular carcinoma (HCC) at elevated threat of disease recurrence has encountered that the investigation fulfilled its immediate endpoint of recurrence-free survival (RFS). Also, 9 out of 10 patients of HCC are induced by chronic liver condition, such as includes alcohol-related liver disease, chronic hepatitis B and C infection, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and cirrhosis resulting from these disorders.

Geographical Analysis

North America is Expected to Dominate the Global Market

The increasing approvals and growing research activities of North America based key players are expected to boost the regional market growth dominating the global market. For instance, in August, 2023, Ocean’s small molecule nominee particularly prevents fibrosis advancement in idiopathic pulmonary fibrosis (IPF) and Hermansky-Pudlak Syndrome (HPS) in multiple testing standards, it was also granted patent for usage in IPF, HPS, alcoholic liver condition, nonalcoholic steatohepatitis (NASH), and scleroderma.

Moreover, in November, 2022, Intercept Pharmaceuticals, Inc. is an American biopharmaceutical corporation reported its strategies concentrated in designing its next-generation FXR agonist, INT-787, in severe alcohol-associated hepatitis (sAH). Alcohol-related liver disease is presently the top indication for liver transplant listing in the U.S., with a significant growth in patients with sAH requiring liver transplantation. Presently, there are no drugs with an authorized indication for the treatment of sAH.

COVID-19 Impact Analysis

Bunches of analysis have connected the pandemic to an upsurge in heavy drinking and a growth in alcohol-related liver disease (ARLD), with a disproportionate effect on females. Total casualties concerning alcohol grew 25% in 2020, with a 22% growth in alcohol-associated liver disorder casualties.

Moreover, according to the UK government rates of visits to hospitals for the alcoholic liver condition in the financial year ending 2021 stood at the highest at 45.5 per 100,000 population, a total of 24,544 admissions they have been since the financial year completing 2011, and are extremely more elevated compared to in the financial year ending 2020. In a recent analysis publicized in Liver International, investigators at Henry Ford Health System have uncovered that individuals hospitalized for alcoholic hepatitis rose a staggering 50% in the early months of the COVID-19 pandemic. Thus, the rise in the number of patients with alcohol-related liver diseases including hepatitis has led to an increase in the demand for the treatment positively impacting the global market.

Key Developments
• In June 2023, DURECT Corporation, a biopharmaceutical corporation designing epigenetic treatments for the treatment of acute organ injuries and chronic liver conditions, finished enrollment in its Phase 2b AHFIRM clinical investigation (NCT04563026) examining larsucosterol for the treatment of individuals with extreme alcohol-associated hepatitis (AH), reaching its registration target of 300 patients.
• In May 2023, Seal Rock Therapeutics, Inc., a clinical-stage corporation designing first-in-class and best-in-class kinase inhibitors, formed an out-licensing deal with GENFIT for the development of an injectable formulation of SRT-015 for an acute liver condition, including Acute-on-Chronic Liver Failure (ACLF).
• In December 2022, Aldeyra Therapeutics, Inc. demonstrated target attention and advancement in the indications of alcohol intoxication in a sequence-randomized, double-masked, placebo-controlled crossover Phase 2 clinical investigation of ADX-629, a first-in-class orally administered investigational unique medicine nominee.

Competitive Landscape

The major global players in the market include Sanofi, Lupin Limited, Genentech, Inc., Teva Pharmaceutical Industries Limited, Pfizer Inc., Alkermes Public Limited Company, Torrent Pharmaceuticals Limited, Wellona Pharma, And Viatris Inc. among others.

Why Purchase the Report?
• To visualize the global alcoholic hepatitis treatment market segmentation based on drug type, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of alcoholic hepatitis treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global alcoholic hepatitis treatment market report would provide approximately 61 tables, 59 figures and 186 pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies